<DOC>
	<DOCNO>NCT00972257</DOCNO>
	<brief_summary>The propose study compare first time quality 24-hour IOP control Brimonidine/Timolol fix combination ( BTFC ) versus Dorzolamide/Timolol fix combination ( DTFC ) run-in period 2 month timolol . This crossover comparison may determine real efficacy two fixed combination design propose study may explain first time 24-hour IOP reduction provide BTFC less might anticipate .</brief_summary>
	<brief_title>24-hr Intraocular Pressure Control With Dorzolamide/Timolol v Brimonidine/Timolol Fixed Combination</brief_title>
	<detailed_description />
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Dorzolamide</mesh_term>
	<mesh_term>Brimonidine Tartrate</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<criteria>Consecutive , newly diagnose previously untreated POAG patient Patients typical glaucomatous disc , visual field damage Patient must IOP ( 10:00 ± 1 hour ) great 25 mm Hg Uncontrolled glaucoma Distance best correct Snellen visual acuity bad 1/10 Contraindications brimonidine dorzolamide βblockers History lack response ( &lt; 10 % morning IOP reduction ) medication Patient understand instruction adhere medication Patient female childbearing potential lactating mother Prior surgery , past use steroid ( within 2 month ) Severe dry eye use contact lens History nonadherence Patients close angle</criteria>
	<gender>All</gender>
	<minimum_age>29 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>24-hour IOP control</keyword>
	<keyword>primary open-angle glaucoma</keyword>
	<keyword>brimonidine/timolol</keyword>
	<keyword>dorzolamide/timolol</keyword>
</DOC>